Patent SG-11201909708V-A (SG)
Title: Methods and antibodies for diabetes-related applications
Inventor: CHOREV MICHAEL
IPC: G01N33/68
Filed: 2018-04-17
Abstract: FigA ELISA of Urine with anti-Amadori mAb y A 0.2703x + QOM Calibration curve \" ay \" Synthetic Peptide Hybrid (rig/ml] Fig. 1B ELISA of Urine with anti-Amadori mAb 1.5 0.75 3 Urine dilution (%) 3.0 2.5 Diabetic with high GCD59 (D2) 2.0 o w' 1 5 D. • 1.0 0.5 0.0 0.18 0.37 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT omit VIII °nolo mu loonmoiflo oimIE (10) International Publication Number WO 2018/195008 Al W O 20 18/ 195 008 Al (51) International Patent Classification: C12N 5/12 (2006.01) C07K 16/28 (2006.01) C12N 15/13 (2006.01) C07C 271/22 (2006.01) CO7K 1/00 (2006.01) G01N 33/53 (2006.01) C07K 1/107 (2006.01) G01N 33/68 (2006.01) (21) International Application Number: PCT/US2018/027856 (22) International Filing Date: 17 April 2018 (17.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,346 21 April 2017 (21.04.2017) US (71) Applicant: MELLITUS, LLC [US/US]; CIC Boston, 50 Milk Street, 16th floor, Boston, Massachusetts 02109 (US). (72) Inventors: CHOREV, Michael; 205 South Street, Chest- nut Hill, Massachusetts 02467 (US). HALPERIN, Jose A.; 1433 Beacon Street, Brookline, Massachusetts 02146 (US). (74) Agent: WARD, Donna T. et al.; DT WARD, P.C., 142A MAIN STREET, GROTON, Massachusetts 01450 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS (57) : Anti-CD59 and anti-glycated CD59 antibodies are disclosed. Assays, diagnostics, kits, and assay components including such antibodies are provided. Methods for the assessment of diabetes-related indications are included as well as inhibitors of CD59 glycation and methods of evaluating such inhibitors.